XNYS
SNN
Market cap11bUSD
Oct 08, Last price
26.96USD
1D
0.26%
1Q
-12.18%
Jan 2017
-10.37%
Name
Smith & Nephew PLC
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Smith & Nephew plc is a global medical technology enterprise dedicated to the development, manufacturing, and worldwide commercialization of an extensive array of medical devices. Its product portfolio spans several key areas. In orthopedics, the company provides knee implants for replacement procedures, hip implants for joint reconstruction, and trauma and extremities products, including both internal and external fixation devices, crucial for stabilizing severe fractures and correcting deformities. For sports medicine, Smith & Nephew offers joint repair solutions tailored for surgeons. This includes specialized instruments, advanced technologies, and implants essential for minimally invasive joint surgeries, targeting soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. Additionally, the firm supplies arthroscopic enabling technologies that enhance surgical visualization and intervention within joints. This suite encompasses fluid management equipment for surgical access, high-definition cameras, digital imaging capture systems, scopes, light sources, and monitors. It also features radiofrequency, electromechanical, and mechanical tissue resection devices, alongside hand instruments for precise tissue removal. The company also provides dedicated ear, nose, and throat (ENT) solutions. Its Advanced Wound Management division delivers comprehensive solutions for the treatment and prevention of acute and chronic wounds, covering conditions like leg, diabetic, and pressure ulcers, burns, and post-operative wounds. This segment includes advanced wound bioactives, comprising biologics and other bioactive technologies for debridement, dermal repair, and regeneration. Regenerative medicine products, such as skin, bone graft, and articular cartilage substitutes, are also offered. Furthermore, Smith & Nephew provides advanced wound devices, including traditional and single-use negative pressure wound therapy systems, and hydrosurgery technology. Primarily serving healthcare providers globally, Smith & Nephew plc was founded in 1856 and is headquartered in Watford, United Kingdom.
Related entities
Subsidiaries (12)
PLUS ORTHOPEDICS HELLAS S.A.
SMITH & NEPHEW ASIA PACIFIC PTE. LIMITED
SMITH & NEPHEW ESN LIMITED
SMITH & NEPHEW GBS PRIVATE LIMITED
SMITH & NEPHEW HEALTHCARE PRIVATE LIMITED
SMITH & NEPHEW HELLAS S.A.
SMITH & NEPHEW MANUFACTURING AG
SMITH & NEPHEW OPERATIONS B.V.
SMITH & NEPHEW ORTHOPAEDICS AG
SMITH & NEPHEW UK LIMITED
SMITH & NEPHEW, INC.
T.J.SMITH AND NEPHEW,LIMITED
Key people
Non-Executive Independent Chairman of the Board · since 2023
John Rogers
Chief Financial Officer, Executive Director · since 2024
Paul Connolly
President - Global Operations
Craig Gaffin
President - Orthopaedics · since 2024
Rohit Kashyap
President - Advanced Wound Management and Global Commercial Operations · since 2023
Vasant Padmanabhan
President Research & Development, ENT and Emerging Markets · since 2024
Scott Schaffner
President - Sports Medicine · since 2023
Elga Lohler
Chief Human Resources Officer · since 2015
Alison Parkes
Chief Compliance Officer
Deepak Nath
Chief Executive Officer, Executive Director · since 2022
Phil Cowdy
Chief Corporate Development and Corporate Affairs Officer · since 2022
Ajay Dhankhar
Chief Corporate Development & Strategy Officer · since 2025
Mizanu Kebede
Chief Quality and Regulatory Affairs Officer · since 2022
Helen Barraclough
Group General Counsel, Company Secretary · since 2022
Jo Hallas
Non-Executive Independent Director · since 2022
David King
Non-Executive Independent Director · since 2025
Independent Non-Executive Director · since 2025
Non-Executive Independent Director · since 2024
John Ma
Non-Executive Independent Director · since 2021
Jeremy Maiden
Non-Executive Independent Director · since 2023
Headquarters & legal address
BUILDING 5, CROXLEY PARK
HATTERS LANE
WATFORD, HRT WD18 8YE
GB
HATTERS LANE
WATFORD, HRT WD18 8YE
GB
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||